Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: A 1 year follow-up study in Shanghai

Psychiatry Research

Volumn 215, Issue 1, 2014, Pages 20-25

  Zhang, Hong Xia ^a   Shen, Xiao Ling ^b   Zhou, Hui ^b   Yang, Xiao Min ^b   Wang, Hui Fang ^b   Jiang, Kai Da ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Drug therapy; Prognosis; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CLONAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ARTICLE; CHINA; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; ICD-10; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; SCORING SYSTEM; SLEEP DISORDER; TREATMENT DURATION;

DRUG THERAPY; PROGNOSIS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHINA; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892851405     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.10.022     Document Type: Article

References (33)

1. Amminger G.P., Resch F., Mutschlechner R., Friedrich M.H., Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode psychosis. European Child & Adolescent Psychiatry 1997, 6:212-218.
2. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 2005, 162:441-449.
3. Birchwood M. Early intervention and sustaining the management of vulnerability. Australian and New Zealand Journal of Psychiatry 2000, 34:S181-S184.
4. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry 1991, 48:239-246.
5. Brissos S., Dias VV., Balanzá-Martinez V., Carita A.I., Figueira M.L. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophrenia Research 2011, 129:133-136.
6. Chang W.C., Tang J.Y., Hui C.L., Lam M.M., Chan S.K., Wong G.H., Chiu C.P., Chen E.Y. Prediction of remission and recovery in young people presenting with first-episode psychosis in Hong Kong: a 3-year follow-up study. Australian and New Zealand Journal of Psychiatry 2012, 46:100-108.
7. Crespo-Facorro B., Pelayo-Terán J.M., Pérez-Iglesias R., Ramírez-Bonilla M., Martínez-García O., Pardo-García G., Vázquez-Barquero J.L. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 2007, 41:659-666.
8. Crespo-Facorro B., de la Foz V.O., Ayesa-Arriola R., Pérez-Iglesias R., Mata I., Suarez-Pinilla P., Tabares-Seisdedos R., Vázquez-Barquero J.L. Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study. Prog. Neuropsychopharmacol. Biological Psychiatry 2013, 44:162-167.
9. Ciudad A., Alvarez E., Bobes J., San L., Polavieja P., Gilaberte I Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophrenia Research 2009, 108:214-222.
10. Eaton W.W., Martins S.S., Nestadt G., Bienvenu O.J., Clarke D., Alexandre P. The burden of mental disorders. Epidemiologic Reviews 2008, 30:1-14.
11. Eberhard J., Levander S., Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Comprehensive Psychiatry 2009, 50:200-208.
12. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research 2007, 89:129-139.
13. Karadayi G., Emiroǧlu B., Uçok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Comprehensive Psychiatry 2011, 52:701-707.
14. Kaur T., Cadenhead K.S. Treatment implications of the schizophrenia prodrome. Current Topics in Behavioral Neurosciences 2010, 4:97-121.
15. Lasser R.A., Nasrallah H., Helldin L., Peuskens J., Kane J., Docherty J., Tronco A.T. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophrenia Research 2007, 96:223-231.
16. Liu T.Q., Yang D.S., Hao W., Wang X.P., Yang L.L. Outcome of schizophrenia: prognostic factors and prediction. Chinese Journal of Clinical Psychology 1997, 5:207-211.
17. Maat A., Fett A.K., Derks E., GROUP Investigators Social cognition and quality of life in schizophrenia. Schizophrenia Research 2012, 137:212-218.
18. Peng X., Ascher-Svanum H., Faries D.E., Stauffer V.L., Kollack-Walker S., Kinon B.J., Kane J.M. Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. ClinicoEconomics and Outcomes Research 2011, 3:79-87.
19. Phillips M.R., Zhang J.X., Shi Q.C., Song Z., Ding Z., Pang S., Li X., Zhang Y., Wang Z. Prevalence, associated disability and treatment of mental disorders in four provinces in China, 2001-2005: an epidemiological survey. Lancet 2009, 373:2041-2053.
20. Polari A., Lavoie S., Sarrasin P., Pellanda V., Cotton S., Conus P. Duration of untreated psychosis: a proposition regarding treatment definition. Early Intervention in Psychiatry 2011, 5:301-308.
21. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M., Fleischhacker W.W. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. Journal of Clinical Psychiatry 2004, 65:1211-1218.
22. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999, 156:544-549.
23. Si T.M., Yang J.Z., Shu L., Wang X.L., Kong Q.M., Zhou M., Li X.N., Liu C. The reliability, validity of PANSS and its implication. Chinese Mental Health Journal 2004, 18:45-47.
24. Smelson D.A., Dixon L., Craig T., Remolina S., Batki S.L., Niv N., Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs 2008, 22:903-916.
25. Spellmann I., Riedel M., Schennach R., Seemüller F., Obermeier M., Musil R., Jäger M, Schmauß M., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Rüther E., Klingberg S., Gastpar M., Möller H.J. One-year functional outcomes of naturalistically treated patients with schizophrenia. Psychiatry Research 2012, 198:378-385.
26. Stowkowy J., Addington D., Liu L., Hollowell B., Addington J. Predictors of disengagement from treatment in an early psychosis program. Schizophrenia Research 2012, 136:7-12.
27. Suryani L.K., Lesmana C.B., Tiliopoulos N. Treating the untreated: applying a community-based, culturally sensitive psychiatric intervention to confined and physically restrained mentally ill individuals in Bali, Indonesia. European Archives of Psychiatry and Clinical Neuroscience 2011, 261:S140-S144.
28. Thirthalli J., Channaveerachari N.K., Subbakrishna D.K., Cottler L.B., Varghese M., Gangadhar B.N. Prospective study of duration of untreated psychosis and outcome of never-treated patients with schizophrenia in India. Indian Journal of Psychiatry 2011, 53:319-323.
29. Uçok A., Polat A., Genç A., Cakir S., Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. Journal of Psychiatric Research 2004, 38:163-168.
30. Valmaggia L.R., McGuire P.K., Fusar-Poli P., Howes O., McCrone P. Economic impact of early detection and early intervention of psychosis. Current Pharmaceutical Design 2012, 18:592-595.
31. Xiang Y.T., Wang Y., Wang C.Y., Chiu H.F.K., Chen Q., Chan S.S.M. Association of insight with sociodemographic and clinical factors, quality of life, and cognition in Chinese patients with schizophrenia. Comprehensive Psychiatry 2012, 53:140-144.
32. Yang X.M., Zhang H.X., Wang H.F., Zhou H., Jiang K.D. Efficacy and side effects of monotherapy risperidone, olanzapine and quetiapine in previously untreated patients with schizophrenia: a one-year prospective cohort study. Shanghai Archives of Psychiatry 2011, 23:137-147.
33. Zhou M., Xie S.P. Factors associated with prognosis of first-episode schizophrenia. Shandong Archives of Psychiatry 2006, 19:9-10.